BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Grebely J, Applegate TL, Cunningham P, Feld JJ. Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis. Expert Review of Molecular Diagnostics 2017;17:1109-15. [DOI: 10.1080/14737159.2017.1400385] [Cited by in Crossref: 75] [Cited by in F6Publishing: 62] [Article Influence: 15.0] [Reference Citation Analysis]
Number Citing Articles
1 Aleman S, Söderholm J, Büsch K, Kövamees J, Duberg AS. Frequent loss to follow-up after diagnosis of hepatitis C virus infection: A barrier towards the elimination of hepatitis C virus. Liver Int 2020;40:1832-40. [PMID: 32294288 DOI: 10.1111/liv.14469] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
2 Lazarus JV, Picchio C, Dillon JF, Rockstroh JK, Weis N, Buti M. Too many people with viral hepatitis are diagnosed late — with dire consequences. Nat Rev Gastroenterol Hepatol 2019;16:451-2. [DOI: 10.1038/s41575-019-0177-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
3 Day E, Hellard M, Treloar C, Bruneau J, Martin NK, Øvrehus A, Dalgard O, Lloyd A, Dillon J, Hickman M, Byrne J, Litwin A, Maticic M, Bruggmann P, Midgard H, Norton B, Trooskin S, Lazarus JV, Grebely J; International Network on Hepatitis in Substance Users (INHSU). Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. Liver Int 2019;39:20-30. [PMID: 30157316 DOI: 10.1111/liv.13949] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 9.8] [Reference Citation Analysis]
4 Lazarus JV, Pericàs JM, Colombo M, Ninburg M, Wiktor S, Thursz M. Viral hepatitis: "E" is for equitable elimination. J Hepatol 2018;69:762-4. [PMID: 30049544 DOI: 10.1016/j.jhep.2018.06.018] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
5 Litwin AH, Drolet M, Nwankwo C, Torrens M, Kastelic A, Walcher S, Somaini L, Mulvihill E, Ertl J, Grebely J. Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: The C-SCOPE Study. J Viral Hepat 2019;26:1094-104. [PMID: 31074167 DOI: 10.1111/jvh.13119] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
6 Mangia A, Rina MF, Canosa A, Piazzolla V, Squillante MM, Agostinacchio E, Cocomazzi G, Visaggi E, Augello N, Iannuzziello C, Falcone M, De Giorgi A, Campanozzi F. Increased Hepatitis C virus screening, diagnosis and linkage to care rates among people who use drugs through a patient-centered program from Italy. United European Gastroenterol J 2021;9:1109-18. [PMID: 34697911 DOI: 10.1002/ueg2.12156] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Brunner N, Bruggmann P. Trends of the Global Hepatitis C Disease Burden: Strategies to Achieve Elimination. J Prev Med Public Health 2021;54:251-8. [PMID: 34370938 DOI: 10.3961/jpmph.21.151] [Reference Citation Analysis]
8 Jacka BP, Bazerman LB, Dickerson C, Moody M, Martin J, Patry E, Cady T, Compere H, Boudreau M, Beckwith CG. Feasibility of hepatitis C virus testing and linkage in community supervision offices: Great potential but persistent challenges. International Journal of Drug Policy 2022;103:103668. [DOI: 10.1016/j.drugpo.2022.103668] [Reference Citation Analysis]
9 Martínez I, Ryan P, Valencia J, Resino S. The Challenging Road to Hepatitis C Virus Eradication. J Clin Med 2021;10:611. [PMID: 33562818 DOI: 10.3390/jcm10040611] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Jiménez-mendoza J, Rivera-lópez F, González-lara M, Valdez-echeverría R, Castro-narro G, Tore A, Uscanga-domínguez L, Moctezuma-velázquez C. Seroprevalence of hepatitis B and C viruses in moderate and severe COVID-19 inpatients: a cross-sectional study at a referral center in Mexico. Annals of Hepatology 2022. [DOI: 10.1016/j.aohep.2022.100684] [Reference Citation Analysis]
11 Biondi MJ, Feld JJ. Hepatitis C models of care: approaches to elimination. CanLivJ 2020;3:165-76. [DOI: 10.3138/canlivj.2019-0002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
12 Girardin F, Hearmon N, Negro F, Eddowes L, Bruggmann P, Castro E. Increasing hepatitis C virus screening in people who inject drugs in Switzerland using rapid antibody saliva and dried blood spot testing: A cost-effectiveness analysis. J Viral Hepat 2019;26:236-45. [DOI: 10.1111/jvh.13023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
13 Koo V, Tian F, Wong WWL. Cost-effectiveness analysis of hepatitis C virus (HCV) point-of-care assay for HCV screening. Liver Int 2021. [PMID: 34847288 DOI: 10.1111/liv.15123] [Reference Citation Analysis]
14 Sharafi H, Poustchi H, Azimian F, Tamadoni B, Ramezani R, Gouya MM, Sheikh M, Hashemi F, Tashakorian M, Alasvand R, Alavian SM, Merat S. Performance of a rapid diagnostic test for screening of hepatitis C in a real-life prison setting. J Clin Virol 2019;113:20-3. [PMID: 30825832 DOI: 10.1016/j.jcv.2019.02.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
15 García F, Domínguez-Hernández R, Casado M, Macías J, Téllez F, Pascasio JM, Casado MÁ, Alados JC. The simplification of the diagnosis process of chronic hepatitis C is cost-effective strategy. Enferm Infecc Microbiol Clin (Engl Ed) 2019;37:634-41. [PMID: 30982677 DOI: 10.1016/j.eimc.2019.03.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
16 Lazarus JV, Pericàs JM, Picchio C, Cernosa J, Hoekstra M, Luhmann N, Maticic M, Read P, Robinson EM, Dillon JF. We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade. J Intern Med 2019;286:503-25. [PMID: 31472002 DOI: 10.1111/joim.12972] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 11.7] [Reference Citation Analysis]
17 Martinello M, Bajis S, Dore GJ. Progress Toward Hepatitis C Virus Elimination: Therapy and Implementation. Gastroenterol Clin North Am 2020;49:253-77. [PMID: 32389362 DOI: 10.1016/j.gtc.2020.01.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
18 Duchesne L, Dussault C, Godin A, Maheu-Giroux M, Kronfli N. Implementing opt-out hepatitis C virus (HCV) screening in Canadian provincial prisons: A model-based cost-effectiveness analysis. Int J Drug Policy 2021;:103345. [PMID: 34176704 DOI: 10.1016/j.drugpo.2021.103345] [Reference Citation Analysis]
19 Lazarus JV, Pericàs JM, Elsharkawy AM. Leaving behind pegylated interferon-based regimens to eliminate hepatitis C as a public health threat by 2030 as set out by WHO. Liver Int 2018;38:1902-5. [PMID: 30358061 DOI: 10.1111/liv.13944] [Reference Citation Analysis]
20 Wang AE, Hsieh E, Turner BJ, Terrault N. Integrating Management of Hepatitis C Infection into Primary Care: the Key to Hepatitis C Elimination Efforts. J Gen Intern Med 2022. [PMID: 35484367 DOI: 10.1007/s11606-022-07628-9] [Reference Citation Analysis]
21 Williams B, Howell J, Doyle J, Thompson AJ, Draper B, Layton C, Latham N, Bramwell F, Membrey D, Mcpherson M, Roney J, Stoové M, Hellard ME, Pedrana A. Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study. Int J Drug Policy 2019;72:91-8. [PMID: 31129023 DOI: 10.1016/j.drugpo.2019.05.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
22 Catlett B, Carrera A, Starr M, Applegate TL, Lowe P, Grebely J, Philip Cunningham H. Performance evaluation of the Hologic Aptima HCV Quant Dx assay for detection of HCV RNA from dried blood spots. J Clin Virol 2019;112:40-4. [PMID: 30776575 DOI: 10.1016/j.jcv.2019.01.010] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
23 Madden A, Hopwood M, Neale J, Treloar C. Acceptability of Patient-Reported Outcome and Experience Measures for Hepatitis C Treatment Among People Who Use Drugs. Patient 2019;12:259-65. [PMID: 30270403 DOI: 10.1007/s40271-018-0332-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
24 Kronfli N, Dussault C, Chalifoux S, Kavoukian H, Klein MB, Cox J. A randomized pilot study assessing the acceptability of rapid point-of-care hepatitis C virus (HCV) testing among male inmates in Montreal, Canada. Int J Drug Policy 2020;85:102921. [PMID: 32911319 DOI: 10.1016/j.drugpo.2020.102921] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
25 Biondi MJ, van Tilborg M, Smookler D, Heymann G, Aquino A, Perusini S, Mandel E, Kozak RA, Cherepanov V, Kowgier M, Hansen B, Goneau LW, Janssen HLA, Mazzulli T, Cloherty G, de Knegt RJ, Feld JJ. Hepatitis C Core-Antigen Testing from Dried Blood Spots. Viruses 2019;11:E830. [PMID: 31489933 DOI: 10.3390/v11090830] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
26 Crespo J, Lázaro de Mercado P, Blasco Bravo AJ, Aguilera Guirao A, García-samaniego Rey J, Eiros Bouza JM, Luis Calleja Panero J, García F. El diagnóstico de la infección por el virus de la hepatitis C en España: una oportunidad para mejorar. Enfermedades Infecciosas y Microbiología Clínica 2019;37:231-8. [DOI: 10.1016/j.eimc.2018.05.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 5.3] [Reference Citation Analysis]
27 Marshall AD, Grebely J, Dore GJ, Treloar C. Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists-The practitioner experience. Drug Alcohol Depend 2020;206:107705. [PMID: 31718924 DOI: 10.1016/j.drugalcdep.2019.107705] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
28 Antuori A, Montoya V, Piñeyro D, Sumoy L, Joy J, Krajden M, González-Gómez S, Folch C, Casabona J, Matas L, Colom J, Saludes V, Martró E; HepCdetect II Study Group. Characterization of Acute HCV Infection and Transmission Networks in People Who Currently Inject Drugs in Catalonia: Usefulness of Dried Blood Spots. Hepatology 2021;74:591-606. [PMID: 33609288 DOI: 10.1002/hep.31757] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
29 Catlett B, Lamoury FMJ, Bajis S, Hajarizadeh B, Martinez D, Mowat Y, Cunningham PH, Jacka BP, Cloherty GA, Marks P, Dore GJ, Grebely J, Applegate TL. Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort study. J Viral Hepat 2019;26:1423-30. [PMID: 31448470 DOI: 10.1111/jvh.13196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
30 Carvalho TL, Mertens Brainer de Queiroz Lima AC, de Araújo NS, de Sousa Fernandes MS, Lira GB, de Melo MMM, Vasconcelos LRS, de Moura PMMF, da Cunha Correia C. Aspects of cognitive assessments and spectroscopic magnetic resonance imaging in people with chronic hepatitis C: a systematic review. Psychol Health Med 2022;:1-17. [PMID: 35075963 DOI: 10.1080/13548506.2022.2029915] [Reference Citation Analysis]
31 Bajis S, Applegate TL, Grebely J, Matthews GV, Dore GJ. Novel Hepatitic C Virus (HCV) Diagnosis and Treatment Delivery Systems: Facilitating HCV Elimination by Thinking Outside the Clinic. J Infect Dis 2020;222:S758-72. [PMID: 33245354 DOI: 10.1093/infdis/jiaa366] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Cox AL, El-Sayed MH, Kao JH, Lazarus JV, Lemoine M, Lok AS, Zoulim F. Progress towards elimination goals for viral hepatitis. Nat Rev Gastroenterol Hepatol 2020;17:533-42. [PMID: 32704164 DOI: 10.1038/s41575-020-0332-6] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 25.5] [Reference Citation Analysis]
33 Vallejo A, Moldes LM, Trigo M, Ordoñez P, Rodriguez-Otero L, Cabrera JJ, Gude MJ, Navarro D, Cañizares A, García-Campello M, Agulla A, Aguilera A; en nombre del Grupo de Estudio del DUSP en Galicia. Generalized implementation of reflex testing of hepatitis C in Galicia: Results for reflection. Enferm Infecc Microbiol Clin (Engl Ed) 2021:S0213-005X(21)00025-2. [PMID: 33632540 DOI: 10.1016/j.eimc.2020.12.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Crespo J, Lázaro P, Blasco AJ, Aguilera A, García-Samaniego J, Eiros JM, Calleja JL, García F. Hepatitis C reflex testing in Spain in 2019: A story of success. Enferm Infecc Microbiol Clin (Engl Ed) 2021;39:119-26. [PMID: 32451150 DOI: 10.1016/j.eimc.2020.03.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
35 Kåberg M, Weiland O. Hepatitis C elimination - Macro-elimination. Liver Int 2020;40 Suppl 1:61-6. [PMID: 32077600 DOI: 10.1111/liv.14352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
36 Grebely J, Hajarizadeh B, Lazarus JV, Bruneau J, Treloar C; International Network on Hepatitis in Substance Users. Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all. Int J Drug Policy 2019;72:1-10. [PMID: 31345644 DOI: 10.1016/j.drugpo.2019.07.016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
37 Gibbs D, Grebely J, Sutherland R, Larney S, Butler K, Dietze PM, Starr M, Peacock A. Concordance between self-reported and current hepatitis C virus infection status in a sample of people who inject drugs in Sydney and Canberra, Australia. Drug Alcohol Rev 2021. [PMID: 33759276 DOI: 10.1111/dar.13282] [Reference Citation Analysis]
38 Krajden M, Cook D, Janjua NZ. Contextualizing Canada’s hepatitis C virus epidemic. CanLivJ 2018;1:218-30. [DOI: 10.3138/canlivj.2018-0011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Draper BL, Htay H, Pedrana A, Yee WL, Howell J, Pyone Kyi K, Naing W, Sanda Aung K, Markby J, Easterbrook P, Bowring A, Aung W, Sein YY, Nwe N, Myint KT, Shilton S, Hellard M. Outcomes of the CT2 study: A 'one-stop-shop' for community-based hepatitis C testing and treatment in Yangon, Myanmar. Liver Int 2021. [PMID: 34153155 DOI: 10.1111/liv.14983] [Reference Citation Analysis]
40 Thedja MD, Wibowo DP, El-Khobar KE, Ie SI, Setiawan L, Murti IS, Muljono DH; Turyadi. Improving Linkage to Care of Hepatitis C: Clinical Validation of GeneXpert® HCV Viral Load Point-of-Care Assay in Indonesia. Am J Trop Med Hyg 2021:tpmd201588. [PMID: 33999849 DOI: 10.4269/ajtmh.20-1588] [Reference Citation Analysis]
41 Yousafzai MT, Alavi M, Valerio H, Hajarizadeh B, Grebely J, Dore GJ. Timely Hepatitis C RNA Testing and Treatment in the Era of Direct-Acting Antiviral Therapy among People with Hepatitis C in New South Wales, Australia. Viruses 2022;14:1496. [PMID: 35891474 DOI: 10.3390/v14071496] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Holmes DT. Self-Ordering Laboratory Testing: Limitations When a Physician Is not Part of the Model. Clin Lab Med 2020;40:37-49. [PMID: 32008638 DOI: 10.1016/j.cll.2019.11.002] [Reference Citation Analysis]
43 Coluccio ML, Pullano SA, Vismara MFM, Coppedè N, Perozziello G, Candeloro P, Gentile F, Malara N. Emerging Designs of Electronic Devices in Biomedicine. Micromachines (Basel) 2020;11:E123. [PMID: 31979030 DOI: 10.3390/mi11020123] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
44 Bajis S, Grebely J, Hajarizadeh B, Applegate T, Marshall AD, Ellen Harrod M, Byrne J, Bath N, Read P, Edwards M, Gorton C, Hayllar J, Cock V, Peterson S, Thomson C, Weltman M, Jefferies M, Wood W, Haber P, Ezard N, Martinello M, Maher L, Dore GJ; LiveRLife Study Group. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study. J Viral Hepat 2020;27:281-93. [PMID: 31698545 DOI: 10.1111/jvh.13233] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
45 Saludes V, Antuori A, Lazarus JV, Folch C, González-Gómez S, González N, Ibáñez N, Colom J, Matas L, Casabona J, Martró E. Evaluation of the Xpert HCV VL Fingerstick point-of-care assay and dried blood spot HCV-RNA testing as simplified diagnostic strategies among people who inject drugs in Catalonia, Spain. Int J Drug Policy 2020;80:102734. [PMID: 32470849 DOI: 10.1016/j.drugpo.2020.102734] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
46 Agarwal R, Gupta E, Kumar G, Singh KK, Sharma MK. Evaluation of true point of care molecular assay using fingerstick capillary whole blood for diagnosis of hepatitis C infection. J Med Microbiol 2021;70. [PMID: 33704042 DOI: 10.1099/jmm.0.001332] [Reference Citation Analysis]
47 Madden A, Hopwood M, Neale J, Treloar C. Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs? PLoS One 2018;13:e0207226. [PMID: 30500863 DOI: 10.1371/journal.pone.0207226] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 7.8] [Reference Citation Analysis]
48 Messina V, Russo A, Parente E, Russo G, Raimondo T, Salzillo A, Simeone F, Onorato L, Di Caprio G, Pisaturo M, Coppola N. Innovative procedures for micro-elimination of HCV infection in persons who use drugs. J Viral Hepat 2020;27:1437-43. [PMID: 32810330 DOI: 10.1111/jvh.13375] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
49 Walters F, Burwell G, Mitchell JJ, Ali MM, Daghigh Ahmadi E, Mostert AB, Jenkins CA, Rozhko S, Kazakova O, Guy OJ. A Rapid Graphene Sensor Platform for the Detection of Viral Proteins in Low Volume Samples. Advanced NanoBiomed Research. [DOI: 10.1002/anbr.202100140] [Reference Citation Analysis]
50 Latham NH, Pedrana A, Doyle JS, Howell J, Williams B, Higgs P, Thompson AJ, Hellard ME. Community‐based, point‐of‐care hepatitis C testing: perspectives and preferences of people who inject drugs. J Viral Hepat 2019;26:919-22. [DOI: 10.1111/jvh.13087] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
51 Grebely J, Catlett B, Jayasinghe I, Valerio H, Hajarizadeh B, Verich A, Cunningham P, Martinello M, Tillakeratne S, Silk D, Dore GJ, Applegate TL. Time to Detection of Hepatitis C Virus Infection With the Xpert HCV Viral Load Fingerstick Point-of-Care Assay: Facilitating a More Rapid Time to Diagnosis. The Journal of Infectious Diseases 2020;221:2043-9. [DOI: 10.1093/infdis/jiaa037] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
52 Shahid I, Alzahrani AR, Al-Ghamdi SS, Alanazi IM, Rehman S, Hassan S. Hepatitis C Diagnosis: Simplified Solutions, Predictive Barriers, and Future Promises. Diagnostics (Basel) 2021;11:1253. [PMID: 34359335 DOI: 10.3390/diagnostics11071253] [Reference Citation Analysis]
53 Lazarus JV, Øvrehus A, Demant J, Krohn-Dehli L, Weis N. The Copenhagen test and treat hepatitis C in a mobile clinic study: a protocol for an intervention study to enhance the HCV cascade of care for people who inject drugs (T'N'T HepC). BMJ Open 2020;10:e039724. [PMID: 33168560 DOI: 10.1136/bmjopen-2020-039724] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Abid A, Uddin M, Muhammad T, Awan S, Applegate T, Dore GJ, Cloherty G, Hamid S. Evaluation of Hepatitis C Virus Core Antigen Assay in a Resource-Limited Setting in Pakistan. Diagnostics (Basel) 2021;11:1354. [PMID: 34441289 DOI: 10.3390/diagnostics11081354] [Reference Citation Analysis]
55 Saludes V, Antuori A, Folch C, González N, Ibáñez N, Majó X, Colom J, Matas L, Casabona J, Martró E; HepCdetect II Study Group. Utility of a one-step screening and diagnosis strategy for viremic HCV infection among people who inject drugs in Catalonia. Int J Drug Policy 2019;74:236-45. [PMID: 31706159 DOI: 10.1016/j.drugpo.2019.10.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
56 Ryan P, Valencia J, Cuevas G, Torres-Macho J, Troya J, Pueyo Á, José Muñoz-Gómez M, Muñoz-Rivas N, Vázquez-Morón S, Martinez I, Lazarus JV, Resino S. Detection of active hepatitis C in a single visit and linkage to care among marginalized people using a mobile unit in Madrid, Spain. Int J Drug Policy 2021;96:103424. [PMID: 34429222 DOI: 10.1016/j.drugpo.2021.103424] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Bajis S, Maher L, Treloar C, Hajarizadeh B, Lamoury FMJ, Mowat Y, Schulz M, Marshall AD, Cunningham EB, Cock V, Ezard N, Gorton C, Hayllar J, Smith J, Whelan M, Martinello M, Applegate TL, Dore GJ, Grebely J; LiveRLife Study Group. Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia. Int J Drug Policy 2018;61:23-30. [PMID: 30388566 DOI: 10.1016/j.drugpo.2018.08.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
58 Morris L, Selvey L, Williams O, Gilks C, Kvassy A, Smirnov A. Hepatitis C cascade of care at an integrated community facility for people who inject drugs. J Subst Abuse Treat 2020;114:108025. [PMID: 32527512 DOI: 10.1016/j.jsat.2020.108025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
59 Marshall AD, Pawlotsky J, Lazarus JV, Aghemo A, Dore GJ, Grebely J. The removal of DAA restrictions in Europe – One step closer to eliminating HCV as a major public health threat. Journal of Hepatology 2018;69:1188-96. [DOI: 10.1016/j.jhep.2018.06.016] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 13.3] [Reference Citation Analysis]
60 Bwa AH, Nangia G, Win STS, Maung ST, Han KAW, Htar SS, Wine LY, Ko WW, Oo MP, Hlaing NKT, Palecki J, Loza BL, Win KM, Reddy R. Strategy and Efficacy of Generic and Pan-genotypic Sofosbuvir/Velpatasvir in Chronic Hepatitis C Virus: A Myanmar Experience. J Clin Exp Hepatol 2019;9:283-93. [PMID: 31360020 DOI: 10.1016/j.jceh.2018.12.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
61 Applegate TL, Fajardo E, Sacks JA. Hepatitis C Virus Diagnosis and the Holy Grail. Infectious Disease Clinics of North America 2018;32:425-45. [DOI: 10.1016/j.idc.2018.02.010] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
62 Cunningham EB, Wheeler A, Hajarizadeh B, French CE, Roche R, Marshall AD, Fontaine G, Conway A, Valencia BM, Bajis S, Presseau J, Ward JW, Degenhardt L, Dore GJ, Hickman M, Vickerman P, Grebely J. Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2022:S2468-1253(21)00471-4. [PMID: 35303490 DOI: 10.1016/S2468-1253(21)00471-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
63 Viganò M, Andreoni M, Perno CF, Craxì A, Aghemo A, Alberti A, Andreone P, Babudieri S, Bonora S, Brunetto MR, Bruno R, Bruno S, Calvaruso V, Caporaso N, Cartabellotta F, Ceccherini-Silberstein F, Cento V, Ciancio A, Colombatto P, Coppola N, Di Marco V, Di Perri G, Fagiuoli S, Gaeta GB, Gasbarrini A, Lampertico P, Pellicelli A, Prestileo T, Puoti M, Raimondo G, Rizzardini G, Taliani G, Zignego AL. Real life experiences in HCV management in 2018. Expert Rev Anti Infect Ther 2019;17:117-28. [PMID: 30582384 DOI: 10.1080/14787210.2019.1563755] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
64 Biondi MJ, Feld JJ. Hepatitis C models of care: approaches to elimination. CanLivJ 2020;3:165-76. [DOI: 10.3138/canlivj-2019-0002] [Reference Citation Analysis]
65 González Grande R, Santaella Leiva I, López Ortega S, Jiménez Pérez M. Present and future management of viral hepatitis. World J Gastroenterol 2021; 27(47): 8081-8102 [DOI: 10.3748/wjg.v27.i47.8081] [Reference Citation Analysis]
66 Selfridge M, Cunningham EB, Milne R, Drost A, Barnett T, Lundgren K, Guarasci K, Grebely J, Fraser C. Direct-acting antiviral treatment for hepatitis C, reinfection and mortality among people attending an inner-city community health centre in Victoria, Canada. Int J Drug Policy. 2019;72:106-113. [PMID: 31178254 DOI: 10.1016/j.drugpo.2019.03.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
67 Terrault NA. Hepatitis C elimination: challenges with under-diagnosis and under-treatment. F1000Res. 2019;8:F1000 Faculty Rev-54. [PMID: 30687501 DOI: 10.12688/f1000research.15892.1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
68 Duchesne L, Hejblum G, Njouom R, Touré Kane C, Toni TD, Moh R, Sylla B, Rouveau N, Attia A, Lacombe K. Model-based cost-effectiveness estimates of testing strategies for diagnosing hepatitis C virus infection in Central and Western Africa. PLoS One 2020;15:e0238035. [PMID: 32833976 DOI: 10.1371/journal.pone.0238035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
69 Chevaliez S. Strategies for the improvement of HCV testing and diagnosis. Expert Rev Anti Infect Ther 2019;17:341-7. [PMID: 30950298 DOI: 10.1080/14787210.2019.1604221] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
70 Aguilera A, Alados JC, Alonso R, Eiros JM, García F. Current position of viral load versus hepatitis C core antigen testing. Enferm Infecc Microbiol Clin (Engl Ed) 2020;38 Suppl 1:12-8. [PMID: 32111360 DOI: 10.1016/j.eimc.2020.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Grebely J, Read P, Cunningham EB, Weltman M, Matthews GV, Dunlop A, Montebello M, Martinello M, Gilliver R, Marks P, Applegate TL, Dore GJ; DARLO‐C Study Group. Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO-C): An open-label, single-arm, phase 4, multicentre trial. Health Sci Rep 2020;3:e151. [PMID: 32270056 DOI: 10.1002/hsr2.151] [Reference Citation Analysis]
72 Heffernan A, Cooke GS, Nayagam S, Thursz M, Hallett TB. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Lancet. 2019;393:1319-1329. [PMID: 30704789 DOI: 10.1016/s0140-6736(18)32277-3] [Cited by in Crossref: 116] [Cited by in F6Publishing: 52] [Article Influence: 38.7] [Reference Citation Analysis]
73 Casas P, Navarro D, Aguilera A, García F. Diagnóstico tradicional versus diagnóstico en un solo paso del virus de la hepatitis C. Estudio piloto en 2 centros asistenciales. Enfermedades Infecciosas y Microbiología Clínica 2019;37:348-9. [DOI: 10.1016/j.eimc.2018.05.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
74 Remy A, Bouchkira H, Hervet J, Happiette A, Wenger H, Tang R. Successful Cascade of Care and Cure HCV in 5382 Drugs Users: How Increase HCV Treatment by Outreach Care, Since Screening to Treatment. JDDD 2017;1:27-35. [DOI: 10.14302/issn.2574-4526.jddd-19-2770] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
75 Day E, Broder T, Bruneau J, Cruse S, Dickie M, Fish S, Grillon C, Luhmann N, Mason K, Mclean E, Trooskin S, Treloar C, Grebely J. Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs. International Journal of Drug Policy 2019;66:87-93. [DOI: 10.1016/j.drugpo.2019.01.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
76 López-Martínez R, Arias-García A, Rodríguez-Algarra F, Castellote-Bellés L, Rando-Segura A, Tarraso G, Vargas-Accarino E, Montserrat-Lloan I, Blanco-Grau A, Caballero-Garralda A, Ferrer-Costa R, Pumarola-Sunye T, Buti-Ferret M, Esteban-Mur R, Quer J, Casis-Saez E, Rodríguez-Frías F. Significant Improvement in Diagnosis of Hepatitis C Virus Infection by a One-Step Strategy in a Central Laboratory: an Optimal Tool for Hepatitis C Elimination? J Clin Microbiol 2019;58:e01815-19. [PMID: 31694971 DOI: 10.1128/JCM.01815-19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]